Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Total Liabilities (2021 - 2026)

Indivior Pharmaceuticals has reported Total Liabilities over the past 6 years, most recently at $1.3 billion for Q1 2026.

  • For Q1 2026, Total Liabilities fell 19.22% year-over-year to $1.3 billion; the TTM value through Mar 2026 reached $1.3 billion, down 19.22%, while the annual FY2025 figure was $1.3 billion, 21.31% down from the prior year.
  • Total Liabilities for Q1 2026 was $1.3 billion at Indivior Pharmaceuticals, up from $1.3 billion in the prior quarter.
  • Over five years, Total Liabilities peaked at $1.9 billion in Q4 2023 and troughed at -$1.9 billion in Q3 2023.
  • A 5-year average of $363.5 million and a median of $1.3 billion in 2026 define the central range for Total Liabilities.
  • On a YoY basis, Total Liabilities climbed as much as 215.04% in 2025 and fell as far as 21.31% in 2025.
  • Year by year, Total Liabilities stood at $1.7 billion in 2022, then increased by 13.04% to $1.9 billion in 2023, then dropped by 14.93% to $1.7 billion in 2024, then decreased by 21.31% to $1.3 billion in 2025, then increased by 3.15% to $1.3 billion in 2026.
  • Business Quant data shows Total Liabilities for INDV at $1.3 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.6 billion in Q3 2025.